



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #52-16) 10/14/2016
DNIB Unwind, Inc. (f/k/a BIND Therapeutics, Inc.) (BINDQ)

Notice has been received that the above Debtors' Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation filed of the Federal Bankruptcy Code, became effective on 10/11/2016. Pursuant to the Plan, on the Effective Date, all BIND Equity Interests shall be cancelled.

For thorough details, please consult the Company's Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

¹ See e.g., *In re DNIB Unwind, Inc. (f/k/a Blind Therapeutics, Inc, et al.*, NO. 16-11084 (BLS) (Debtors' Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation)